MedicineCardiologyPharmacologyCardiovascular PharmacotherapyHemodynamic ManagementInflammationAnti-inflammatory PharmacologyCardiac PharmacotherapyCardiovascular DiseaseHeart FailureHeart Failure PharmacotherapyOxidative Stress In InflammationCaptopril TherapyCardiac Fibrosis ModulationHeart Failure Molecular MechanismsHeart Failure PharmacologyOxidative Stress InjuryRenin-angiotensin System ModulationRenin-angiotensin-aldosterone SignalingRenin-angiotensin-aldosterone System Activation
AIM: Qi-shen-yi-qi (QSYQ), a formula used for the routine treatment of heart failure (HF) in China, has been demonstrated to improve cardiac function through down-regulating the activation of the Renin-Angiotensin-Aldosterone System (RAAS). However, the mechanisms governing its therapeutic effects are largely unknown. The present study aims to demonstrate that QSYQ treatment can prevent left ventricular remodeling in heart failure by attenuating oxidative stress and inhabiting inflammation. METHODS: Sprague-Dawley (SD) rats were randomly divided into 6 groups: sham group, model group (LAD coronary artery ligation), QSYQ group with high dosage, middle dosage and low dosage (LAD ligation and treated with QSYQ), and captopril group (LAD ligation and treated with captopril as the positive drug). Indicators of fibrosis (Masson, MMPs, and collagens) and inflammation factors were detected 28 days after surgery. RESULTS: Results of hemodynamic alterations (dp/dt value) in the model group as well as other ventricular remodeling (VR) markers, such as MMP-2, MMP-9, collagen I and III elevated compared with sham group. VR was accompanied by activation of RAAS (angiotensin II and NADPHoxidase). Levels of pro-inflammatory cytokines (TNF-α, IL-6) in myocardial tissue were also up-regulated. Treatment of QSYQ improved cardiac remodeling through counter-acting the aforementioned events. The improvement of QSYQ was accompanied with a restoration of angiotensin II-NADPHoxidase-ROS-MMPs pathways. In addition, "therapeutic" QSYQ administration can reduce both TNF-α-NF-B and IL-6-STAT3 pathways, respectively, which further proves the beneficial effects of QSYQ. CONCLUSIONS: Our study demonstrated that QSYQ protected LAD ligation-induced left VR via attenuating AngII -NADPH oxidase pathway and inhabiting inflammation. These findings provide evidence as to the cardiac protective efficacy of QSYQ to HF and explain the beneficial effects of QSYQ in the clinical application for HF.
17
Nox4 Is a Protective Reactive Oxygen Species Generating Vascular NADPH Oxidase
Katrin Schröder, Min Zhang, Sebastian Benkhoff et al. · Circulation Research · 2012 · 614 citations · Full text
Mohanraj Rajesh, Partha Mukhopadhyay, Sándor Bátkai et al. · Journal of the American College of Cardiology · 2010 · 490 citations · Full text
Medicine, Cardiology, Pharmacology +17
Divergent Tumor Necrosis Factor Receptor–Related Remodeling Responses in Heart Failure
Tariq Hamid, Yan Gu, Roger V. Ortines et al. · Circulation · 2009 · 275 citations · Full text
Medicine, Cardiology, Immunology +16